Skip to main content
EMYRIA LIMITED logo

EMYRIA LIMITED — Investor Relations & Filings

Ticker · EMD ISIN · AU0000073645 LEI · 529900IMZL1QU98KGH07 ASX Professional, scientific and technical activities
Open in API
Filings indexed 440 across all filing types
Latest filing 2026-05-17 Regulatory Filings
Country AU Australia
Listing ASX EMD

About EMYRIA LIMITED

https://emyria.com

Emyria Limited is a clinical-stage biotechnology company focused on developing and delivering new treatments for mental health and neurological conditions. The company integrates clinical service delivery with data-driven drug development to accelerate the path to market for novel therapies. Emyria operates a network of specialist clinics that provide evidence-based care while collecting high-quality real-world data to inform its drug discovery pipeline. Key focus areas include MDMA-assisted therapy for post-traumatic stress disorder (PTSD) and the development of proprietary cannabinoid-based medicines. Through its partnership with clinical research organizations and mental health specialists, the company aims to provide scalable, data-backed solutions for complex health challenges. Its proprietary data platform supports the identification of new drug targets and the optimization of clinical trial designs.

Recent filings

Filing Released Lang Actions
Emyria Activates First Victorian Empax Clinic 3 pages 557.2KB
Regulatory Filings Classification · 90% confidence The document is an ASX release announcing the operational start of a new clinic, with no substantive financial statements, earnings metrics, or financing details. It is a general corporate operational update filed on the exchange, not a formal report (e.g., Annual Report, Interim Report) or a specific transaction notice. It therefore falls into the ‘Regulatory Filings’ category as a miscellaneous ASX disclosure.
2026-05-17 English
March Quarter Investor Video Presentation 13 pages 2.9MB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX release dated 5 May 2026 titled 'March Quarter Investor Video Presentation' by Emyria Limited. It includes a detailed investor presentation with slides, discussing the company's quarterly achievements, future catalysts, clinic utilization data up to 30 April 2026, and strategic updates. The content focuses on operational and financial highlights for the March quarter, including revenue figures and clinical outcomes, which are typical of quarterly investor updates. The document is about 15,000 characters long, indicating it is a substantive report rather than a brief announcement. It is not a full annual report (10-K), nor an earnings release (which would be shorter and more focused on headline financials), but rather a comprehensive quarterly report with financial data and business analysis. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-05-04 English
Results of General Meeting 2 pages 107.8KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement addressed to the Australian Securities Exchange regarding the results of a General Meeting held by Emyria Limited. It references Listing Rule 3.13.2 and section 251AA of the Corporations Act, which pertain to disclosure of voting outcomes. The content includes detailed voting results for various resolutions, indicating the outcome of shareholder votes. The document is short (2984 characters) and focuses solely on the voting results of the meeting, not on the meeting materials or the meeting itself. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). There is no indication that this is a full report or presentation, nor is it a proxy solicitation or management information. Therefore, the correct classification is DVA with high confidence.
2026-04-30 English
Emyria Extends National Expansion into New South Wales 4 pages 214.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 29 April 2026 from Emyria Limited announcing a new partnership to expand their national clinic footprint into New South Wales. It details the business expansion, new clinic locations, workforce recruitment, and strategic partnerships. The content focuses on operational updates, partnership agreements, and business development rather than financial results, regulatory filings, or detailed financial statements. There is no indication of quarterly or annual financial data, audit information, or executive compensation details. The document is a corporate announcement about a capital expansion and partnership agreement, which fits best under Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes through new partnerships and clinic expansions. The document length (over 10,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice. Therefore, the classification is CAP with high confidence.
2026-04-28 English
March 2026 Quarterly Activities Report and Appendix 4C 10 pages 571.2KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX release dated 28 April 2026 titled 'Quarterly Activities and Cash Flow Report' for the quarter ended 31 March 2026. It contains detailed operational updates, clinical outcomes, business expansion information, and a comprehensive Appendix 4C cash flow statement with actual financial data for the quarter. The presence of substantive financial data and analysis for a quarter shorter than a full fiscal year indicates this is a quarterly report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-04-27 English
Ignite Investment Summit Singapore Presentation 15 pages 3.8MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation prepared by Emyria Limited for the Ignite Investment Summit Singapore in April 2026. It contains extensive information about the company's business model, market opportunity, treatment protocols, clinical results, shareholder information, and strategic positioning. The content is structured as a corporate overview and investor-focused presentation, including disclaimers, forward-looking statements, and detailed data on mental health market size and treatment efficacy. There are no financial statements, audit opinions, or regulatory certifications present. The document is not a transcript of a call, nor is it a voting result or legal proceeding update. It is clearly designed to inform investors about the company's strategy, market, and progress, which fits the definition of an Investor Presentation (IP). The length and detail confirm it is the presentation itself, not just an announcement or summary.
2026-04-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.